UNIVERSITAS GADJAH MADA
Luaran Klinis dan Biaya Medis Langsung Cisplatin-Paclitaxel dibandingkan Carboplatin-Paclitaxel pada Pasien Non-Small Cell Lung Cancer (NSCLC) Stadium Lanjut di RSUP Dr. Sardjito
Gustia Alinda Lintarsari, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS.; Dr. apt. Fita Rahmawati, Sp.FRS.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Afifah, N. N., Permatasari, L. I., Diantini, A., Intania, R., Wijaya, I., Obinata, H. dkk. 2024, Exploring Genetic Variants and Platinum Chemotherapy Response in Indonesian Non-Small Cell Lung Cancer Patients: Insights from ERCC2 rs13181, *OncoTargets and therapy*, **17**:767–776

Alaswad, M. 2023, Locally advanced non-small cell lung cancer: current issues and recent trends, *Rep Pract Oncol Radiother*, **28**: 286-303.

Alfarisyi, A.M.A., Hasanah, N., dan Moerad, E.B. 2025, Karakteristik Pasien Non-Small Cell Lung Carcinoma di RSUD Abdoel Wahab Sjahranie Samarinda, *JIKK*, **12**:1023-1033.

Alvarez, A.A.R., Sun, Y., Li, Y., dan Christiani, D.C. 2025, Effects of Sex on Mortality in Patients with Lung Cancer: A Multiple Mediation Analysis of The Boston Lung Cancer Study, *Clin Lung Cancer*, **27**:201-209.

American Cancer Society. 2017, *Cancer Facts and Figures 2017*, Atlanta, American Cancer Society, diakses pada 12 Maret 2025, <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf>

American Thoraic Society. 2022, Treatment of Advanced-Stage Non-Small Cell Lung Cancer, *Am J Respir Crit Care Med*, **205**: 9-10.

Andayani, T.M. 2013, *Farmakoekonomi Prinsip dan Metodologi*, Yogyakarta, Bursa Ilmu.

Andriani M. 2019, 'Analisis Biaya Terapi pada Penyakit Kanker Paru Rawat Inap Jaminan Kesehatan Nasional di RSI Sultan Agung Semarang', *Tesis*, M.Pharm.Sci., Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta.

Asmara, O.D., Tenda, E.D., Singh, G., Pitoyo, C.W., Rumende, C.M., Rajabto, W., dkk. 2023, Lung Cancer in Indonesia, *J Thorac Oncol*, **18**:1134–1145.

Ben-Aharon, O., Magnezi, R., Leshno, M., dan Goldstein, D.A. 2019, Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers? *Oncologist*, **24**:1469–1478.

Buja, A., Di Pumpo, M., Rugge, M., Zorzi, M., Rea, F., Pantaleo, I., dkk. 2025, Patterns of Comorbidities in Lung Cancer Patients and Survival, *Cancers*, **17**:1577

UNIVERSITAS GADJAH MADA
Luaran Klinis dan Biaya Medis Langsung Cisplatin-Paclitaxel dibandingkan Carboplatin-Paclitaxel pada Pasien Non-Small Cell Lung Cancer (NSCLC) Stadium Lanjut di RSUP Dr. Sardjito
Gustia Alinda Lintarsari, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS.; Dr. apt. Fita Rahmawati, Sp.FRS.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Buja, A., Rugge, M., Di-Pumpo, M., Zorzi, M., Rea, F., Pantaleo, I., dkk. 2025, Healthcare Costs by Comorbidity Patterns in Lung Cancer Patients, *Cancers*, **17**:2682

Buz, M., dan Dincer, S. 2022, Association between histologic subtypes of non-small cell lung cancer and survival: Retrospective cohort analysis of 1887 patients, *South Clin Ist Euras*, **33**:442-447

Camerini, A., Del-Conte, A., Pezzuto, A., Scotti, V., Facchinetti, F., Ciccone, L.P., dkk. 2022, Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial, *Cancers*, **14**:1-10

Chen, Y.M., Perng, R.P., Tsai, C.M., dan Whang-Peng, J. 2006, A Phase II Randomized Study of Paclitaxel Plus Carboplatin or Cisplatin against Chemo-Naive Inoperable Non-small Cell Lung Cancer in the Elderly, *J Thorac Oncol*, **1**:141-145.

Chirikos, T.N., Roetzheim, R.G., McCarthy, E.P., dan Iezzoni, L.I. 2008, Cost disparities in lung cancer treatment by disability status, sex, and race, *Disabil Health J*, **1**:108-115.

Chan, H.F., Hsu, W.H., Chen, J.P. dan Lee, J.H. 2024, Factors associated with survival of patients with advanced lung cancer and long travel distances, *J Formos Med Assoc*, **123**:273-282.

Chouaid, C., Dujon, C., Do, P., Monnet, I., Madroszyk, A., Le Caer, H., dkk. 2014, Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01), *Lung Cancer*, **86**:170–173.

Darmawan, E.S., Permanasari, V.Y., Salma, N., dan Lubis, A.P. 2019, *Memahami Kebijakan Kelas Rawat Inap Standar Rumah Sakit*, Surabaya, Pustaka Saga Jawadwipa.

Delgado, A. dan Guddati, A. K. 2021, Clinical endpoints in oncology-a primer, *Am J Cancer Res*, **11**:1121-1131.

Dingillo, G., Bassiri, A., Badrinathan, A., Alvarado, C. E., Sinopoli, J., Tapias, L., dkk. 2023, Lung Cancer in Young Patients is Associated With More Advanced Disease but Better Overall Survival, *J Surg Res*, **292**:307–316

UNIVERSITAS
GADJAH MADA
**Luaran Klinis dan Biaya Medis Langsung Cisplatin-Paclitaxel dibandingkan Carboplatin-Paclitaxel pada
Pasien Non-Small Cell Lung Cancer (NSCLC) Stadium Lanjut di RSUP Dr. Sardjito**
Gustia Alinda Lintarsari, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS.; Dr. apt. Fita Rahmawati, Sp.FRS.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

DiPiro, J.T., Yee, G.C., Haines, S.T., Nolin, T.D., Ellingrod, V. dan Posey, L.M. 2023, *DiPiro's Pharmacotherapy: a Pathophysiologic Approach*, 12th edition, New York, Mc Graw Hill.

Driscoll, J.J. dan Rixe, O. 2009, Overall survival: still the gold standard why overall survival remains the definitive end point in cancer clinical trials, *Cancer J*, **15**:401-405.

Duma, N., Santana-Davila, R., dan Molina, J. R. 2019, Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment, *Mayo Clinic Proceedings*, **94**:1623-1640.

Edelman, M.J. dan Rupard, E.J. 2006, Chemotherapeutic Agents, *Elsevier*, 332-338.

Elsaka, O., Noureldean, A., Gamil, M.A., Ghazali, T., Hamada, A., Al-Razik, A., dkk. 2022, Etiology, investigations, and treatment in cases of non-small cell lung cancer. *J. Basic Appl. Res. Biomed*, **5**:22–48.

Gandeware, T. C. 2017, 'Studi Biaya Kemoterapi Kombinasi Taxan Base dengan Platinum Base pada Pasien Kanker Paru di RSUD Dr. Soetomo Surabaya', Skripsi, S.Fam., Fakultas Farmasi, Universitas Katolik Widya Mandala, Surabaya.

Ghosh, S. 2019, Cisplatin: The first metal based anticancer drug, *Bioorg. Chem,* **88**:1-20.

Hana, J. dan Faizah, N.N. 2023, Diagnostic approach of lung cancer: A literature review. *JR*, **9**:141–149.

Iachina, M., Green, A. dan Jakobsen, E. 2014, The direct and indirect impact of comorbidity on the survival of patients with non-small cell lung cancer: a combination of survival, staging and resection models with missing measurements in covariates. *BMJ open*, **4**:1-5.

International Agency for Research on Cancer. 2022, Global Cancer Observatory, World Health Organization, diakses pada 6 Februari 2025, < https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf>

Isobe, H., Mori, K., Minato, K., Katsura, H., Taniguchi, K., Arunachalam, A., dkk. 2017, Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan. *Lung Cancer*, **8**: 191–206.

UNIVERSITAS
GADJAH MADA
**Luaran Klinis dan Biaya Medis Langsung Cisplatin-Paclitaxel dibandingkan Carboplatin-Paclitaxel pada
Pasien Non-Small Cell Lung Cancer (NSCLC) Stadium Lanjut di RSUP Dr. Sardjito**
Gustia Alinda Lintarsari, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS.; Dr. apt. Fita Rahmawati, Sp.FRS.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Jeon, D. S., Kim, J. W., Kim, S. G., Kim, H. R., Song, S. Y., Lee, J. C., dkk. 2022, Sex differences in the characteristics and survival of patients with non-small-cell lung cancer: A retrospective analytical study based on real-world clinical data of the Korean population. *Thorac cancer*, **13**:2584–2591.

Jovanoski, N., Kaur, G., Shukla, H., Chana, N., dan Kharawala, S. 2026, Economic burden of advanced non-small cell lung cancer (NSCLC): a systematic literature review. *J Med Econ*, **29**:433–454.

Kadota, K., Yeh, Y.C., Sima, C.S., Rusch, V.W., Moreira, A.L., Adusumilli, P.S., dkk. 2014, The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: A conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype, *Mod. Pathol.*, **27**:690–700.

Kementerian Kesehatan. 2013, *Pedoman Penerapan Kajian Farmakoekonomi*, Jakarta, Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan. 2023, *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1438/2023 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Paru*, Jakarta, Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan. 2024, *Rencana Kanker Nasional 2024-2034: Strategi Indonesia dalam Upaya Melawan Kanker*, Jakarta, Kementerian Kesehatan Republik Indonesia.

Koswara, T., Iriawan, J., dan Surya, F. 2022, Characteristics of Non-Small Cell Lung Carcinoma and The Result of Epidermal Growth Factor Receptor Test, *J Health Dent Sci*, **2**:343-354.

Kriegsmann, K., Cremer, M., Zgorzelski, C., Harms, A., Muley, T., Winter, H., Kazdal, D., dkk. 2019, Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer, *Pathol.*, **51**:240–245.

Ku, C.H., Hou, M.M., Tseng, C.K., Yeh, K.Y., Lu, C.H., dan Chou, W.C. 2025, Efficacy and Safety of Chemoradiotherapy with Carboplatin and Paclitaxel in Older Adults with Esophageal Cancer, *J Cancer Res Pract*, **12**:112–120.

Launois, R., Lay, K.L., Chemali, N. dan Vergnenegre, A. 2008, A cost-minimization analysis of first line polychemotherapy regimens in the treatment of advanced non small cell lung cancer, *PAJO*, **1**:28-43.

Lemeshow, S. 1990, *Adequacy of Sample Size in Health Studies*, England, John Wiley & Sons Ltd.

UNIVERSITAS
GADJAH MADA
**Luaran Klinis dan Biaya Medis Langsung Cisplatin-Paclitaxel dibandingkan Carboplatin-Paclitaxel pada
Pasien Non-Small Cell Lung Cancer (NSCLC) Stadium Lanjut di RSUP Dr. Sardjito**
Gustia Alinda Lintarsari, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS.; Dr. apt. Fita Rahmawati, Sp.FRS.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Li, F., Li, F., Lu, H., dan Zhao, D. 2025a, A comparative study on prognostic differences between men and women with non-small cell lung cancer across different antitumor treatment modalities, *BMC Cancer*, **25**:1802

Li, F., Li, F., Lu, H., dan Zhao, D. 2025b, Analysis of age-related survival differences in advanced non-small cell lung cancer patients based on real-world data, *BMC Cancer*, **25**:1244.

Li, Y., Lin, C., Cui, L., Huang, C., Shi, L., Huang, S., dkk. 2025c, Association between age and lung cancer risk: evidence from lung lobar radiomics, *BMC Med Imaging*, **25**:204.

Li, Y., Noma, T., Liang, L., dan Weng, W. 2026, Sex Differences in Overall Survival Among Patients with Non-Small-Cell Lung Cancer Across Clinical Stages: A Population-Based SEER Study, *Healthcare*, **14**:966.

Luo, L., Hu, Q., Jiang, J.X., Yang, X., Dinglin, X.X., Lin, X., dkk. 2015, Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: A meta-analysis, *Asia Pac. J. Clin. Oncol.*, **11**:253–261.

Minami, H., Kiyota, N., Kimbara, S., Ando, Y., Shimokata, T., Ohtsu, A., Fuse, N., dkk. 2021, Guidelines for clinical evaluation of anti-cancer drugs, *Cancer Sci.*, **112**:2563–2577.

Minervini, F., Lampridis, S., Kestenholz, P., Pardo, E., Crommelinck, J., Putora, P.M., dkk. 2025, The impact of smoking on lung cancer patients, *Eur Respir Rev*, **34**:240175

Mostafa, A.A.B., Al-Akhras, A., Tashtoush, S., dan Hamouri, S. 2023, Impact of Smoking on Survival in NSCLC Patients Treated with Chemoimmunoimmunotherapy or Chemotherapy: A Real-world Data Study, *J Thorac Oncol*, **18**:S420-S421.

Novia J. 2016, 'Biaya Pengobatan Pasien Kanker Paru Karsinoma Non-Sel Kecil Stadium Lanjut (IIIB-IV) yang Mendapat Kemoterapi di Rumah Sakit Kanker Dharmais Jakarta', *Tesis*, M.Kes, Fakultas Kedokteran, Universitas Gadjah Mada, Yogyakarta.

Perin, J., Zarić, B., Đođić, J. E., Potić, Z., Potić, M., Sekeruš, V., dkk. 2018, The cost of hospital treatment of advanced stage lung cancer patients in a developing South East European country. *J Cancer*, **9**:3038–3045

UNIVERSITAS
GADJAH MADA
**Luaran Klinis dan Biaya Medis Langsung Cisplatin-Paclitaxel dibandingkan Carboplatin-Paclitaxel pada
Pasien Non-Small Cell Lung Cancer (NSCLC) Stadium Lanjut di RSUP Dr. Sardjito**
Gustia Alinda Lintarsari, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS.; Dr. apt. Fita Rahmawati, Sp.FRS.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Rajdev, K., Siddiqui, A.H., Ibrahim, U., Patibandla, P., Khan, T. dan El-Sayegh, D. 2018, An Unusually aggressive large cell carcinoma of the lung: Undiagnosed until autopsy, *Cureus*, **10**:1-7.

Ramalingam, S. dan Belani, C.P. 2004, Paclitaxel for non-small cell lung cancer, *Expert Opin Pharmacother*, **5**:1771-1780.

Ramalingam, S., Dinan, M. A., dan Crawford, J. 2018, Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States, *J Thorac Oncol*, **13**:1842–1850.

Rascati, K. L. 2014, *Essentials of Pharmacoeconomics: Second Edition,* Philadelphia, Lippincott Williams & Wilkins.

Rosell, R., Gatzemeier, U., Betticher, D.C., Keppler, U., Macha, H.N., Pirker, R., dkk. 2002, Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial, *Ann Oncol*, **13**:1539–1549.

Rothschild, S. I., Nachbur, R., Herzog, N., Passweg, J. R., dan Pless, M. 2021, Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients. *ESMO open*, **6**:100013

Rubio-Terrés, C., Luis Tisaire, J., Kobina, S., dan Moyano, A. 2002, Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer, *Lung Cancer*, **35**:81-89.

Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., dkk. 2002, Comparison of four chemotherapy regimens for advanced non-small cell lung cancer, *N. Engl. J. Med.*, **346**:92-98.

Sculler, J.P. dan Moro-Sibilot, D. 2009, First- and second-line therapy for advanced non-small cell lung cancer, *Eur Respir J.,* **33**:915–930.

Soetandyo, N., Hanafi, A.R., Agustini, S., dan Sinulingga, D.T. 2020, Prognosis of advanced stage non-small-cell lung cancer patients receiving chemotherapy: Adenocarcinoma versus squamous cell carcinoma, *Med J of Indones*, **29**:26–31.

Sreenivasan, J., dan Mohamedali, S. P. 2018, A prospective observational study on drug safety monitoring and Pharmacoeconomics in patients with locally advanced unresectable NSCLC in a tertiary care hospital, *Int J Basic Clin Pharmacol*, **7**:676–683.

UNIVERSITAS
GADJAH MADA
**Luaran Klinis dan Biaya Medis Langsung Cisplatin-Paclitaxel dibandingkan Carboplatin-Paclitaxel pada
Pasien Non-Small Cell Lung Cancer (NSCLC) Stadium Lanjut di RSUP Dr. Sardjito**
Gustia Alinda Lintarsari, Prof. Dr. apt. Tri Murti Andayani, Sp.FRS.; Dr. apt. Fita Rahmawati, Sp.FRS.
Universitas Gadjah Mada, 2026 | Diunduh dari http://etd.repository.ugm.ac.id/

Tabchi, S., Kassouf, E., Florescu, M., Tehfe, M. dan Blais, N. 2017, Factors influencing treatment selection and survival in advanced lung cancer, *Curr. Oncol.*, **24**:e115–e122.

Tas, F., Ciftci, R., Kilic, L., dan Karabulut, S. 2013, Age is a prognostic factor affecting survival in lung cancer patients, *Oncol Lett*, **6**:1507–1513.

Tsim, S., O'Dowd, C.A., Milroy, R. dan Davidson, S. 2010, Staging of non-small cell lung cancer (NSCLC): A review, *Respir. Med.,* **104**:1767–1774.

Visbal, A. L., Williams, B. A., Nichols, F. C., Marks, R. S., Jett, J. R., Aubry, M. C., dkk. 2004, Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002, *Ann Thorac Surg*, **78**:209–215.

Vogenberg, F.R. 2001, *Introduction to Applied Pharmacoeconomic*, New York, Mc Graw Hill.

Wang, Y., Pond, G., Gafni, A.J., Kong, C.Y., dan Ellis, P. M. 2025, Cost Disparities with Age in the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) in Ontario, Canada, *Curr Oncol*, **32**:1-14.

Weise, A., Büchter, R.B., Pieper, D., dan Mathes, T. 2022, Assessing transferability in systematic reviews of health economic evaluations – a review of methodological guidance, *BMC Med Res Methodol*, **22**:1-13.

Wen, J., Fu, J.H., Zhang, W., dan Guo, M. 2011, Lung carcinoma signaling pathways activated by smoking, *Chin J Cancer,* **30**:551-558.

Zeng, X., Peng, L., Li, J., Chen, G., Tan, C., Wang, S., dkk. 2013, Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: Estimates from the perspective of the chinese health care system, *Clin. Ther.*, **35**:54–65.

Zhou, J., Xu, Y., Liu, J., Feng, L., Yu, J., dan Chen, D. 2024, Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN, *Cancer Epidemiology*, **93**:102693.

Zou, K., Sun, P., Huang, H., Zhuo, H., Qie, R., Xie, Y., dkk. 2022, Etiology of lung cancer: Evidence from epidemiologic studies, *JNCC,* **2**:216–225.